EP1575509A4

Epha2 agonistic monoclonal antibodies and methods of use thereof

Abstract

The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.

Term

Term ended

Projected expiry passed 12 May 2023, 3.4 years ago.

Every citation, both waysCites: the store holds 8 of 9

Citations
Document	Relation	Office	Category	Cited during	Relevant claims
WO0112172A1	Cites	World Intellectual Property Organization (WIPO)	X	Search report	1-76
WO0112840A2	Cites	World Intellectual Property Organization (WIPO)	YX	Search report	1-20
WO0230465A2	Cites	World Intellectual Property Organization (WIPO)	A	Search report	–
WO03094859A2	Cites	World Intellectual Property Organization (WIPO)	LE	Search report	1-76
WO2005051307A2	Cites	World Intellectual Property Organization (WIPO)	T	Search report	–
WO0230465A	Cites	World Intellectual Property Organization (WIPO)	–	–	–
WO03094859A	Cites	World Intellectual Property Organization (WIPO)	–	–	–
WO2005051307A	Cites	World Intellectual Property Organization (WIPO)	–	–	–
ZELINSKI D P ET AL: "EPHA2 OVEREXPRESSION CAUSES TUMORIGENESIS OF MAMMARY EPITHELIAL CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 5, 1 March 2001 (2001-03-01), pages 2301 - 2306, XP001182247, ISSN: 0008-5472	Non-patent	–	–	Search report	–
LANDEN CHARLES N JR ET AL: "Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 1 NOV 2006, vol. 98, no. 21, 1 November 2006 (2006-11-01), pages 1558 - 1570, XP002421774, ISSN: 1460-2105	Non-patent	–	–	Search report	–
BRANTLEY D M ET AL: "Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 21, no. 45, 10 October 2002 (2002-10-10), pages 7011 - 7026, XP002992332, ISSN: 0950-9232	Non-patent	–	–	Search report	–
ZANTEK N D ET AL: "E-CADHERIN REGULATES THE FUNCTION OF THE EPHA2 RECEPTOR TYROSINE KINASE", CELL GROWTH AND DIFFERENTIATION, THE ASSOCIATION, PHILADELPHIA, PA, US, vol. 10, September 1999 (1999-09-01), pages 629 - 638, XP000978524, ISSN: 1044-9523	Non-patent	–	–	Search report	–
EWERT S ET AL: "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 34, no. 2, October 2004 (2004-10-01), pages 184 - 199, XP004526805, ISSN: 1046-2023	Non-patent	–	–	Search report	–

33 members in 10 offices

This recordMember, by publication datePriority claim

Priority claims19

Priority claims
Document	Office	Kind	Date
379368P	United States of America	–	2002-05-10
37936802	United States of America	P	2002-05-10
37936802	United States of America	P	2002-05-10
418204P	United States of America	–	2002-10-14
41820402	United States of America	P	2002-10-14
41820402	United States of America	P	2002-10-14
460358P	United States of America	–	2003-04-03
46035803	United States of America	P	2003-04-03
46035803	United States of America	P	2003-04-03
0315046	United States of America	W	2003-05-12
0315046	United States of America	W	2003-05-12
379368P	–	–	–
418204P	–	–	–
460358P	–	–	–
US20020379368P	–	–	–
US20020418204P	–	–	–
US2003015046	–	–	–
US20030460358P	–	–	–
WO2003US15046	–	–	–

Members33

Family members, oldest first
Document	Office	Kind
CA2485548A1	Canada	A1	2004-02-19
WO2004014292A2	World Intellectual Property Organization (WIPO)	A2	2004-02-19
AU2003276832A1	Australia	A1	2004-02-25
US2004091486A1	United States of America	A1	2004-05-13
AU2004293034A1	Australia	A1	2005-06-09
CA2546763A1	Canada	A1	2005-06-09
WO2005051307A2	World Intellectual Property Organization (WIPO)	A2	2005-06-09
US2005152899A1	United States of America	A1	2005-07-14
EP1575509A2	European Patent Office (EPO)	A2	2005-09-21
WO2004014292A3	World Intellectual Property Organization (WIPO)	A3	2006-02-16
JP2006507013A	Japan	A	2006-03-02
EP1689346A2	European Patent Office (EPO)	A2	2006-08-16
WO2005051307A3	World Intellectual Property Organization (WIPO)	A3	2006-09-07
KR20060135671A	Republic of Korea	A	2006-12-29
CN1905899A	China	A	2007-01-31
US2007086943A1	United States of America	A1	2007-04-19
EP1575509A4This record	European Patent Office (EPO)	A4	2007-04-25
US2007134254A1	United States of America	A1	2007-06-14
EP1689346A4	European Patent Office (EPO)	A4	2007-11-21
JP2008500021A	Japan	A	2008-01-10
AU2009239780A1	Australia	A1	2009-12-10
US2010143345A1	United States of America	A1	2010-06-10
JP4585968B2	Japan	B2	2010-11-24
US2010298545A1	United States of America	A1	2010-11-25
AU2009239780B2	Australia	B2	2011-03-17
CN1905899B	China	B	2011-09-28
EP1575509B1	European Patent Office (EPO)	B1	2011-10-26
AT530577T	Austria	T	2011-11-15
ATE530577T1	Austria	T1	2011-11-15
JP4860477B2	Japan	B2	2012-01-25
AU2004293034B2	Australia	B2	2012-02-02
ES2377720T3	Spain	T3	2012-03-30
AU2012202569A1	Australia	A1	2012-05-24

121 legal events, as 9 offices reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code	Office
2014-08-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-06-10	Announcement of lapse in spainLapsedFD2A	FD2A	ES
2014-05-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-05-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-03-07	Notification of lapseLapsedST	ST	FR
2014-03-06	Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119	R119	DE
2014-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-01-29	Gb: european patent ceased through non-payment of renewal feeCeasedGBPC	GBPC	EP
2013-06-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-02-27	Patent lapsedLapsedMM4A	MM4A	IE
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-12-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-12-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2012-12-31	Patent ceasedCeasedPL	PL	CH
2012-11-29	No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097	R097	DE
2012-10-03	No opposition filedOpposition26N	26N	EP
2012-09-13	Change of applicant/patenteeR081	R081	DE
2012-09-13	Change of applicant/patenteeR081	R081	DE
2012-09-13	Change of applicant/patenteeR081	R081	DE
2012-09-13	Change of applicant/patenteeR081	R081	DE
2012-09-13	Change of applicant/patenteeR081	R081	DE
2012-09-13	Change of applicant/patenteeR081	R081	DE
2012-09-13	Change of applicant/patenteeR081	R081	DE
2012-09-13	Change of applicant/patenteeR081	R081	DE
2012-09-13	Change of representativeR082	R082	DE
2012-08-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-08-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-08-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2012-08-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2012-08-31	No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE	PLBE	EP
2012-08-31	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA	STAA	EP
2012-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-07-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2012-07-24	Change of representativeR082	R082	DE
2012-06-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-04-25	Party data changed (patent owner data changed or rights of a patent transferred)RAP2	RAP2	EP
2012-04-25	Party data changed (patent owner data changed or rights of a patent transferred)RAP2	RAP2	EP
2012-04-15	Deletion acc. to par. 5 (withdrawal of the translation of the ep patent)MK05	MK05	AT
2012-03-30	Definitive protectionFG2A	FG2A	ES
2012-02-29	Party data changed (patent owner data changed or rights of a patent transferred)RAP2	RAP2	EP
2012-02-29	Party data changed (patent owner data changed or rights of a patent transferred)RAP2	RAP2	EP
2012-02-15	Discontinued in the netherlands as no translation has been filedVDEP	VDEP	NL
2012-01-19	Dpma publication of mentioned ep patent grantGrantedR096	R096	DE
2011-11-23	European patents granted designating irelandGrantedFG4D	FG4D	IE
2011-10-31	European patent takes effect as a national patent in ch/liEP	EP	CH
2011-10-26	Designated contracting statesAK	AK	EP
2011-10-26	European patent grantedGrantedFG4D	FG4D	GB
2011-09-23	(expected) grantORIGINAL CODE: 0009210GRAA	GRAA	EP
2011-09-22	Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS	GRAS	EP
2011-06-01	Request for extension of the european patent (deleted)DAX	DAX	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-05-25	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2011-04-27	Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP	GRAP	EP
2011-04-20	Amendment of ipc main classPREVIOUS MAIN CLASS: A61K0006000000R079	R079	DE
2007-10-03	First examination report despatched17Q	17Q	EP
2007-04-25	Supplementary search report drawn up and despatchedA4	A4	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-04-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP

Showing 100 of 121

Epha2 agonistic monoclonal antibodies and methods of use thereof

Abstract

Term

Priority claims19

Members33

Over the term

Events

Numbers

Titles3

Classification

Designated states1